UNSPSC 51383503: Glucametacin

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H27ClN2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N1EXE5EHAN, chemically known as d-glucose, 2-(((1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indol-3-yl)acetyl)amino)-2-deoxy-, hydrate but generally known as glucametacin, which bears US NIH Compound Identifier 3033980. European Medicines Agency schedules Glucametacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07936MIG.

UNSPSC 51383503 Glucametacin, a Commodity code, nominally names a specific pharmaceutical compound, but recent state and local solicitation activity under this code does not align with that narrow scope. Instead, state and local governments are using the code to procure a broader range of pharmaceutical and drug-management products and services, including naloxone, over-the-counter medications, generic pharmaceuticals, and safe drug deactivation systems. The mix of issuing bodies spans county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). Recent solicitations reveal demand for both direct product supply through wholesaler networks and exploratory vendor engagement around direct-to-manufacturer prescription programs designed to improve cost management and fulfillment efficiency.

Recent activity concentrates in Florida and Texas, with broader multistate cooperative reach through Minnesota's MMCAP alliance. The Seminole County IFB (IFB60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to a community health building. The Minnesota MMCAP RFP (S1070000015802, response due March 26, 2026) established standing contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards taking effect July 1, 2026, and vendor responses weighted heavily on price competitiveness (75 percent). The Texas HHS Commission RFI (HHS0017013, response due April 3, 2026) explored vendor capabilities for a direct-to-manufacturer prescription program operating outside traditional pharmacy benefit manager and group purchasing organization channels. All three solicitations require vendors to demonstrate manufacturing compliance (cGMP, DSCSA), maintain robust insurance coverage, and support electronic data interchange and wholesaler integration where applicable.